The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Drug Makers to Continue Production through Golden Week
May 16, 2011
- Liovel, Nexium Recommended for Approval
May 16, 2011
- CHMP Gives Positive Opinion for Avastin, Xeloda Combination: Roche
May 16, 2011
- METI to Subsidize Installation of In-house Power Generators
May 16, 2011
- Simponi Recommended for Approval
May 16, 2011
- FDA Issues Complete Response Letter for Aricept Patch: Eisai
May 16, 2011
- Major Drugstore Chains to Hire More New Graduates from Disaster Areas
May 16, 2011
- Kyowa Kirin Files NDA for Anti-CCR4 Antibody KW-0761
May 16, 2011
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Sawai, Takeda Take Actos Patent Dispute to IP High Court
May 16, 2011
- Long-Acting ESA Mircera Approved: Chugai
May 16, 2011
- Korosho Invites Medical Societies to Present Views on 10 Switch OTC Drug Candidates
May 16, 2011
- DSP Licenses Novel Topical Analgesic to Maruho
May 16, 2011
- Glubes Approved for Type 2 Diabetes: Kissei
May 16, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…